tirzepatide and type 1 diabetes for diabetes: on track to SURPASS current therapy Protecting the hearts of people

Neurotrauma 30 , 981997 (2013)

Kariya Pharmaceuticals has taken a unique approach with KP405, a first-in-class dual GLP-1/GIP receptor agonist with the potential to synergistically reduce neuroinflammation, enhance mitochondrial function and support neuronal survival

Emerging retrospective real-world analyses have suggested a possible association between GLP-1RA use and lower incidence of hypothyroidism, particularly with semaglutide

When considering Tirzepatide vs Semaglutide for weight loss, its essential to understand how these medications differ

Fatigue and reduced energy levels surprise many patients who expect weight loss medications to increase energy

doi: 10.1016/j.metabol.2019.03.004